Advertisement

Antagonists of Growth Hormone-releasing Hormone in Oncology

  • A. V. Schally
Conference paper

Abstract

Growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and, upon binding to specific GHRH receptors in the pituitary, stimulates the synthesis and the release of GH. GHRH is also present in several extrahy-pothalamic tissues, including placenta, ovary, testis, gastrointestinal tract and tumors of neuroendocrine origin (Bagnato et al., 1992). Thus, the presence of GHRH ligand was demonstrated in human prostatic, ovarian, endometrial, mammary and lung cancers, suggesting that GHRH could be a growth factor for these tumors. The identification of growth hormone-releasing hormone (GHRH) was facilitated by the demonstration of ectopic production of GHRH by carcinoid and pancreatic cell tumors (Frohman and Szabo, 1981).

Keywords

Nude Mouse Small Cell Lung Cancer Epithelial Ovarian Cancer Cell Line Human Epithelial Ovarian Cancer Cell Small Cell Lung Cancer Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bagnato A., Moretti C, Ohnishi J., Frajese G. and Catt K.J. (1992). Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology, 130, 1097–1102.PubMedCrossRefGoogle Scholar
  2. Braczkowski R., Schally A.V., Plonowski A., Varga J.L., Groot K., Krupa M. and Armatis P. (2002). Inhibition of proliferation of human MNNG/HOS osteosarcoma and SK-ES-i Ewing’s sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on IGF-2. Cancer, 95, 1735–1745.PubMedCrossRefGoogle Scholar
  3. Busto R., Schally A.V., Braczkowski R., Plonowski A., Krupa M., Groot K., Armatis P. and Varga J.L. (2002a). Expression of mRNA for growth hormone-releasing hormone (GHRH), and splice variants of GHRH receptors in human osteosarcomas. Regul Peptides, 108, 47–53.CrossRefGoogle Scholar
  4. Busto R., Schally A.V., Varga J.L., Garcia-Fernandez M.O., Groot K., Armatis P. and Szepeshazi K. (2002b). The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA, 99, 11866–11871.CrossRefGoogle Scholar
  5. Chatzistamou I., Schally A.V., Varga J.L., Groot K. and Armatis P. (2001a). Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit growth of OV-1063 human epithelial ovarian CA cell line xenografted into nude mice. J Clin Endocrinol Metab, 86, 2144–2152.CrossRefGoogle Scholar
  6. Chatzistamou I., Schally A.V., Varga J.L., Groot K., Busto R., Armatis P. and Haimos G. (2001b). Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anti-cancer Drugs, 12, 761–768.CrossRefGoogle Scholar
  7. Chopin L.K. and Herington A.C. (2001). A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate, 49, 116–121.PubMedCrossRefGoogle Scholar
  8. Csernus V.J., Schally A.V., Kiaris H. and Armatis P. (1999) Inhibition of growth, production of insulin-like growth factor-2 (IGF-2) and expression of IGF-2 mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA, 96, 3098–3103.PubMedCrossRefGoogle Scholar
  9. Frohman L.A. and Szabo M. (1981). Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res, 74, 259–271.PubMedGoogle Scholar
  10. Garcia-Fernandez M.O., Schally A.V., Varga J.L., Groot K. and Busto R. (2003). The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat, 77, 15–26.PubMedCrossRefGoogle Scholar
  11. Guillemin R., Brazeau P., Bohlen P., Esch F., Ling N. and Wehrenberg W.B. (1982). Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science, 218, 585–587.PubMedCrossRefGoogle Scholar
  12. Haimos G., Schally A.V., Varga J.L., Plonowski A., Rekasi Z. and Czompoly T. (2000). Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci USA, 97, 10555–10560.CrossRefGoogle Scholar
  13. Haimos G., Schally A.V., Comaru-Schally A.M., Nagy A. and Irimpen A. (2003). Targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides do not bind to growth hormone secretagogue receptors on human myocardium. Life Sci, 72, 2669–2674.CrossRefGoogle Scholar
  14. Izdebski J., Pinski J., Horvath J.E., Halmos G., Groot K. and Schally A.V. (1995). Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci, USA, 92, 4872–4876.PubMedCrossRefGoogle Scholar
  15. Jaffe C.A., DeMott-Friberg R., Frohman L.A. and Barkan A.L. (1997). Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J Clin Endocrinol Metab, 82, 634–637.PubMedCrossRefGoogle Scholar
  16. Jungwirth A., Schally A.V.,Pinski J., Groot K.,Armatis A. and Halmos G. (1997a). Growth hormone-releasing hormone (GHRH) antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA, 94, 5810–5813.CrossRefGoogle Scholar
  17. Jungwirth A., Schally A.V., Pinski J., Halmos G., Groot K., Armatis P. and Vadillo-Buenfil M. (1997b). Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer, 75, 1585–1592.CrossRefGoogle Scholar
  18. Kahan Z., Arencibia J., Csernus V., Groot K., Kineman R., Robinson W.R. and Schally A.V. (1999). Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab, 84, 582–589.PubMedCrossRefGoogle Scholar
  19. Kahan Z., Varga J.L., Schally A.V., Rekasi Z., Armatis P., Chatzistamou I., Czompoly T. and Halmos G. (2000). Antagonists of growth hormone releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat, 60, 71–79.PubMedCrossRefGoogle Scholar
  20. Kiaris H. and Schally A.V. (1999). Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA, 96, 226–231.PubMedCrossRefGoogle Scholar
  21. Kiaris H., Schally A.V.,Busto R., Halmos G., Artavanis-Tsakonas S. and Varga J.L.(2002). Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci USA, 99, 196–200PubMedCrossRefGoogle Scholar
  22. Kiaris H., Schally A.V. and Varga J.L. (2000a). Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastomas in nude mice. Neoplasia, 2, 242–250.CrossRefGoogle Scholar
  23. Kiaris H., Schally A.V. and Varga J. (2000b). Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin like growth factor 2 in H-69 small cell lung carcinoma. Cancer Lett, 161, 149–155.CrossRefGoogle Scholar
  24. Kiaris H., Schally A.V., Varga J.L., Groot K. and Armatis P. (1999). Growth hormonereleasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA, 96, 14894–14898.PubMedCrossRefGoogle Scholar
  25. Kovacs M., Schally A.V., Lee E-J., Busto R., Armatis P., Groot K. and Varga J.L. (2002). Inhibitory effects of antagonistic analogs of growth hormone-releasing hormone (GHRH) on GH3 pituitary cells expressing the human GHRH receptor. J Endocrinol, 175, 425–434.PubMedCrossRefGoogle Scholar
  26. Lamharzi N., Schally A.V., Koppan M. and Groot K. (1998). Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expres sion of insulin like growth factor 2 in tumors. Proc Natl Acad Sci USA, 95, 8864–8868.PubMedCrossRefGoogle Scholar
  27. Pinski J., Schally A.V., Groot K., Halmos G., Szepeshazi K., Zarandi M. and Armatis P. (1995). Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Nat Cancer Inst, 87, 1787–1794.PubMedCrossRefGoogle Scholar
  28. Pinski J., Schally A.V., Jungwirth A., Groot K., Halmos G., Armatis P., Zarandi M. and Vadillo-Buenfil M. (1996) Inhibition of growth of human small-cell and non-smallcell lung carcinomas by antagonists of growth hormone-releasing hormone (GHRH). Int J Oncol, 9, 1099–1105.PubMedGoogle Scholar
  29. Plonowski A., Schally A.V., Busto R., Krupa M., Varga J.L. and Halmos G. (2002a). Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides, 23, 1127–1133.CrossRefGoogle Scholar
  30. Plonowski A., Schally A.V., Krupa A., Hebert E, Groot K.and Varga J.L. (2002b). The inhibition of proliferation of PC-3 hum an prostate cancer by antagonists of growth hormone-releasing hormone is not correlated with the suppression of serum IGF-l or tumoral IGF-2 and vascular endothelial growth factor. Prostate, 52, 173–182.CrossRefGoogle Scholar
  31. Plonowski A., Schally A.V., Varga J.L., Rekasi Z., Hebert E, Halmos G. and Groot K. (2000). Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate, 44, 172–180.PubMedCrossRefGoogle Scholar
  32. Pollak M.N., Polychronakos C. and Guyda H. (1989). Somatostatin analogue SMS201-995 reduces serum IGF-l levels in patients with neoplasm potentially dependent on IGF1. Anticancer Res, 9, 889–891.PubMedGoogle Scholar
  33. Rekasi Z., Czompoly T., Schally A.V. and Halmos G. (2000). Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA, 97, 10561–10566.PubMedCrossRefGoogle Scholar
  34. Rekasi Z., Schally A.V., Plonowski A., Czompoly T., Csernus B. and Varga J.L. (2001). Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoac tive intestinal peptide. Prostate, 48, 188–199.PubMedCrossRefGoogle Scholar
  35. Rivier J., Spiess J., Thorner M. and Vale W. (1982). Characterization of a growth hormone-releasing factor from a human pancreatic islet tumor. Nature, 300, 276–278.PubMedCrossRefGoogle Scholar
  36. Robberecht P., Coy D., Waelbroeck M., Heiman M., deNeef P., Camus J-C.  and Christophe J. (1985). Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1–29)-NH2 as a GRF antagonist on membranes. Endocrinology, 117, 1759–1764.PubMedCrossRefGoogle Scholar
  37. Schally A.V. and Comaru-Schally A.M. (1998a). Agonisti c analogs of growth hormonereleasing hormone (GHRH): endocrine and growth studies. In Growth Hormone Secretagogues in Clinical Practice, eds Bercu B.B. and Walker R.E, pp. 131–144. New York, Marcel Dekker.Google Scholar
  38. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L. and Halmos G. (2001). Hypothalamic hormones and cancer. Frontiers Neuroendocrinol, 22, 248–291.CrossRefGoogle Scholar
  39. Schally A.V., Comaru-Schally A.M., Plonowski A., Nagy A., Halmos G. and Rekasi Z. (2000). Peptide analogs in the therapy of prostate cancer. Prostate, 45, 158–166.PubMedCrossRefGoogle Scholar
  40. Schally A.V., Kovacs M., Toth K. and Comaru-Schally A.M. (1998b). Antagonistic actions of growth hormone-releasing hormone: endocrine and oncological studies. In Growth Hormone Secretagogues in clinical practice, eds Bercu B.B. and Walker R.E, pp. 145–162. NewYork, Marcel Dekker.Google Scholar
  41. Schally A.V. and Varga J.L. (1999). Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab, 10, 383–391.PubMedCrossRefGoogle Scholar
  42. Szepeshazi K., Schally A.V., Groot K., Armatis P., Halmos G., Hebert E., Szende B., Varga J.L. and Zarandi M. (2000a). Antagonists of growth hormone-releasing hormone (GHRH) decrease IGF-2 Production of HT-29 human colon cancer cells and inhibit tumour growth. Br J Cancer, 82, 1724–1731.CrossRefGoogle Scholar
  43. Szepeshazi K., Schally A.V., Groot K., Armatis P., Hebert E and Halmos G. (2000b). Antagonists of growth hormone-releasing hormone (GHRH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-2 levels in tumors. Eur J Cancer, 36, 128–136.CrossRefGoogle Scholar
  44. Szepeshazi K., Schally A.V., Armatis P., Groot K., Hebert E., Feil A., Varga J.L. and Halmos G. (2001). Antagonists of GHRH decrea se production of GH and IGF-l in MXTmouse mammary cancers and inhibit tumor growth. Endocrinology, 142, 4371–4378.PubMedCrossRefGoogle Scholar
  45. Szereday Z., Schally A.V., Varga J.L., Hebert F., Armatis P., Groot K., Szepeshazi K., Halmos G. and Busto R. (2002). Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res (in press).Google Scholar
  46. Varga J.L., Schally A.V., Csernus V.J., Zarandi M., Halmos G. and Rekasi Z. (1999). Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA, 96, 692–697.PubMedCrossRefGoogle Scholar
  47. Zarandi M., Horvath J.E., Halmos G., Pinski J., Nagy A., Groot K., Rekasi Z. and Schally A.V. (1994). Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA, 91, 12298–12301.PubMedCrossRefGoogle Scholar
  48. Zarandi M., Kovacs M., Horvath J., Toth K., Halmos G., Groot K., Nagy A., Kele Z. and Schally A.V. (1997). Synthesis and in vitro evaluation of new potent antagonists of growth hormone- releasing hormone (GHRH). Peptides, 18, 423–430.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • A. V. Schally

There are no affiliations available

Personalised recommendations